@article{SarukhanyanShityakovDandekar2018,
  author    = {Sarukhanyan, Edita and Shityakov, Sergey and Dandekar, Thomas},
  title     = {In silico designed Axl receptor blocking drug candidates against Zika virus infection},
  series = {ACS Omega},
  volume    = {3},
  journal   = {ACS Omega},
  number    = {5},
  doi       = {10.1021/acsomega.8b00223},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-176739},
  pages     = {5281-5290},
  year      = {2018},
  abstract  = {After a large outbreak in Brazil, novel drugs against Zika virus became extremely necessary. Evaluation of virus-based pharmacological strategies concerning essential host factors brought us to the idea that targeting the Axl receptor by blocking its dimerization function could be critical for virus entry. Starting from experimentally validated compounds, such as RU-301, RU-302, warfarin, and R428, we identified a novel compound 2′ (R428 derivative) to be the most potent for this task amongst a number of alternative compounds and leads. The improved affinity of compound 2′ was confirmed by molecular docking as well as molecular dynamics simulation techniques using implicit solvation models. The current study summarizes a new possibility for inhibition of the Axl function as a potential target for future antiviral therapies.},
  language  = {en}
}
@article{SarukhanyanShityakovDandekar2020,
  author    = {Sarukhanyan, Edita and Shityakov, Sergey and Dandekar, Thomas},
  title     = {Rational drug design of Axl tyrosine kinase type I inhibitors as promising candidates against cancer},
  series = {Frontiers in Chemistry},
  volume    = {7},
  journal   = {Frontiers in Chemistry},
  number    = {920},
  issn      = {2296-2646},
  doi       = {10.3389/fchem.2019.00920},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-199505},
  year      = {2020},
  abstract  = {The high level of Axl tyrosine kinase expression in various cancer cell lines makes it an attractive target for the development of anti-cancer drugs. In this study, we carried out several sets of in silico screening for the ATP-competitive Axl kinase inhibitors based on different molecular docking protocols. The best drug-like candidates were identified, after parental structure modifications, by their highest affinity to the target protein. We found that our newly designed compound R5, a derivative of the R428 patented analog, is the most promising inhibitor of the Axl kinase according to the three molecular docking algorithms applied in the study. The molecular docking results are in agreement with the molecular dynamics simulations using the MM-PBSA/GBSA implicit solvation models, which confirm the high affinity of R5 toward the protein receptor. Additionally, the selectivity test against other kinases also reveals a high affinity of R5 toward ABL1 and Tyro3 kinases, emphasizing its promising potential for the treatment of malignant tumors.},
  language  = {en}
}